Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.

Cancer Biol Med · 2026 · PMC13326598 · PMID 42227592

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although fuzuloparib alone exhibited clinical benefit in HRD patients, the addition of apatinib showed a trend toward improved PFS compared to fuzuloparib monotherapy for patients with HR proficiency [HRP] (16.6 vs. 11.0 months; HR = 0.73), indicating the necessity of drug combination in HRP patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.